It is found that damaging de novo single-nucleotide variants and frameshift indels explain 3.4% (95% CI: 2.1% - 4.7%) of autism variance on the observed scale.
Abstract
De novo mutations in protein-coding regions are strongly associated with autism, and family-based sequencing studies have identified numerous genes that harbor excess mutations in probands. However, the aggregate contribution of this class of variation to autism remains unclear. Here, we model the distribution of de novo autosomal coding variant effect sizes in 38,680 autism trios to estimate fundamental features of de novo genetic architecture. We find that damaging de novo single-nucleotide variants and frameshift indels explain 3.4% (95% CI: 2.1% - 4.7%) of autism variance on the observed scale. Approximately 7.0% (95% CI: 5.6% - 8.4%) of cases carry a large-effect mutation (rate ratio > 5), and most such mutations are incompletely penetrant. Although hundreds of genes make some nonzero contribution, 50% of mutational variance on the autosomes is explained by just 15 genes. De novo enrichments vary across cohorts with different ascertainment strategies; making projections for future trio studies, we show that many large-effect genes remain to be found.
Recent developments have expanded the understanding of the way the genetic basis of autism manifests phenotypically, and illustrate the therapeutic potential of gene-first approaches for selected monogenic neurodevelopmental disorders.
V. Eapen, A. Stylianakis, I. Voineagu· Current Opinion in Psychiatr...· 0 citations
This study finds that rare variants across hundreds of genes contribute to autism with variable phenotypic outcomes, and clusters them based on association evidence from large-scale studies of developmental disorders, schizophrenia, bipolar disorder, and epilepsy.
F. Satterstrom, C. Auwerx, J.-M. Fu et al.· medRxiv· 1 citation
Increased CNV burden, in both number and cumulative genomic size, co-occurred more frequently in individuals with severe phenotypes, including ASD with intellectual disability, epilepsy, and broader NDDs, reflecting a real-world clinical setting rather than a prospectively recruited research cohort.
M. R. Di Iorio, Ilaria La Monica, Antonio Imperatore et al.· International Journal of Mol...· 0 citations
Describing all 16,138 copy number variants found in 3832 patients studied from 2009 to 2024 prompted the description of all CNV findings with patient profiles is needed to optimize CMA potential for presymptomatic diagnosis and therapy.
Santosh Chaval, Sahil S. Tonk, Golder N. Wilson et al.· Current Issues in Molecular...· 0 citations
This study provides the first comprehensive genomic overview of ASD in a large Brazilian cohort, reinforcing the critical need to include diversely admixed populations in genomic research to expand the understanding of ASD architecture and improve diagnostic strategies in resource-limited settings.
Gabriele da Silva Campos, C. I. S. Costa, J. Wang et al.· Genetics and Molecular Biolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
